{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:14:16Z","timestamp":1778933656361,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jdcr.2025.10.072","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:27:41Z","timestamp":1764001661000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["S\u00e9zary syndrome presenting as vitiligo-like leukoderma with response and repigmentation to mogamulizumab and extracorporeal photopheresis"],"prefix":"10.1016","volume":"68","author":[{"given":"Elizabeth","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordyn","family":"Puccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Swick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-9521","authenticated-orcid":false,"given":"Vincent","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2025.10.072_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jdcr.2025.10.072_bib2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10094","key":"10.1016\/j.jdcr.2025.10.072_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jdcr.2025.10.072_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jdcr.2024.04.009","article-title":"S\u00e9zary syndrome associated vitiligo-like leukoderma in type V skin: report of a case and review of the literature","volume":"48","author":"Mirza","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jdcr.2025.10.072_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2133.1987.tb04904.x","article-title":"Generalized vitiligo following S\u00e9zary syndrome","volume":"116","author":"Alcalay","year":"1987","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2025.10.072_bib6","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1046\/j.1365-2133.2000.03851.x","article-title":"Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: four cases. The French Study Group of Cutaneous Lymphomas","volume":"143","author":"Bouloc","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.10.072_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1067\/mjd.2003.11","article-title":"S\u00e9zary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy","volume":"48","author":"Macheiner","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2025.10.072_bib8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1365-2133.2005.06877.x","article-title":"Pathogenetic mechanisms of vitiligo in a patient with S\u00e9zary syndrome","volume":"153","author":"Knol","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2025.10.072_bib9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jdcr.2025.10.072_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1684\/ejd.2021.4002","article-title":"Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: three cases","volume":"31","author":"Algarni","year":"2021","journal-title":"Eur J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625006411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625006411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:42:30Z","timestamp":1778931750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625006411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":10,"alternative-id":["S2352512625006411"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.10.072","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00e9zary syndrome presenting as vitiligo-like leukoderma with response and repigmentation to mogamulizumab and extracorporeal photopheresis","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.10.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}